“Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children’s Oncology Group”

This article, published in “Cancer Genetics”, reports that a high proportion of rare pathogenic TP53 variants in the pediatric patients with osteosarcoma (OS) may be de novo. Guidelines that recommend clinical TP53 genetic testing among all pediatric patients with OS, regardless of family history or number of primary tumors, should continue to be considered. For further information click on the publication title.